Greenville SC

  • Sam Patrick posted an article
    Greenville, SC gains more accolades as a key cog in the state's emerging knowledge economy see more

    Greenville and South Carolina are in the national spotlight again as among America's emerging knowledge economy destinations.  SCBIO supporters Zylo Therapeutics, KIYATEC, VentureSouth and Chartspan are among the features companies in Bloomberg Businessweek's fabulous article.  Read on for the full story.

     

  • Sam Patrick posted an article
    Top Speakers Added for SCBIO 2019 Life Sciences Conference in Greenville October 29-31 see more

    Come Ignite the Future of South Carolina life sciences and join hundreds of industry executives, leaders in government and higher education, and life sciences providers and supporters from across America at SCBIO 2019... October 29-31 in Greenville, SC!

    SCBIO 2019 features 2+ days of incredible presentations, intensive networking, innovation updates, opportunity discovery, partnership making, industry trade show and strategic discussion.  SCBIO 2019 is a must-attend for America's most promising and prominent life sciences organizations! 

    Meet and hear such speakers at Michal Preminger, head of Johnson & Johnson Innovation for North America... Halle Tecco, founder of Natalist and digital health venture fund Rock Health... President Jim Clements of Clemson University... inspirational success story Dean Otto, whose very life was saved by contributions from the industry we share... and dozens more!

    Enjoy world-class accommodations at the Hyatt Regency Greenville... incredible receptions Tuesday (presented by Prisma Health System) and Wednesday (presented by the Greenwood Partnership, Greenville Area Development Corp. and City of Greenville) evenings... and leading-edge discussions on such topics as: 

         -  Turning Education & Research Into Cures & Companies
         -  Building the Life Sciences Workforce of Tomorrow
         -  Igniting & Investing in the Changing Future of Healthcare
         -  Life Sciences Economic Development:  How SC Will Win
         -  Opportunities & Innovations in Life Sciences
         -  Global Trends and Their Implications for You
         -  South Carolina Success Stories & The Leaders Behind Them

    Registration is now open!  Enjoy Early Bird registration and save $100 or more by booking right now. And secure your spot at our headquarters hotel with accommodations at Hyatt Regency Greenville at special rates while they last. 

  • Sam Patrick posted an article
    Prisma Health has named its new President and CEO see more

    Prisma Health announced the selection of Mark S. O’Halla as the health company’s new president and chief executive officer (CEO). O’Halla, along with the members of the executive leadership team, will be responsible for advancing the health company’s goal to create a better state of health in South Carolina by improving clinical quality, the patient experience, access to care, and addressing rising health care costs. O’Halla will join Prisma Health in mid-August.  Prisma Health is a Mission Partner of SCBIO, the life sciences organization of South Carolina.

    O’Halla has been serving as executive vice president/chief operating officer of Michigan-based McLaren Health Care since 2014. He has more than 30 years of progressive experience in health care senior executive roles, including 13 years with the McLaren organization.

    The board of directors was pleased with the high-quality candidates they reviewed for this important role. “We are honored to select Mark as our next leader. We believe his experience leading a multiregional health care system will be a critical element in ensuring Prisma Health continues its journey to transform health care for our communities. We look forward to working with Mark to ensure that South Carolinians get the quality health care they need and deserve,” said James E. “Rick” Wheeler, chair of the Prisma Health board of directors and vice president of M-D Metal Source.

    O’Halla added, “Joining Prisma Health and its 32,000 team members is an exciting opportunity to help redefine and continue improving health care for patients in South Carolina. I am proud to be part of this vibrant new health company, focused on providing exemplary quality, smart growth and sustained financial strength. I am also excited to work with physicians and university partners to advance its academic mission.”

    As the executive vice president/chief operating officer at McLaren Health Care, a 14-hospital system with two health insurance plans covering 583,000 lives, O’Halla spearheaded initiatives to achieve top performance in areas of financial, operating and clinical quality, created a standardized patient-centered focus across the system that improved patient satisfaction, directed the alignment and growth of its Medical Group, and led efforts to integrate various clinical and administrative elements of the health system. 

    O’Halla earned his bachelor’s degree in Accounting and Finance from the University of Toledo, Toledo, Ohio; and master’s degree in Business Administration from William E. Simon Graduate School of Business at the University of Rochester, Rochester, New York. He is active in several health care organizations including American College of Healthcare Executives and served on several community boards.

    O’Halla and his wife, Anita, will be relocating to Greenville, South Carolina. They have three grown children.

    In January, Prisma Health launched the national search for its new CEO to lead the organization formed by the partnership of South Carolina’s largest health care systems, Greenville Health System (GHS), now Prisma Health–Upstate and Palmetto Health, now Prisma Health–Midlands.

    Physicians who participated in O’Halla’s selection look forward to working with him as Prisma Health’s first president and CEO.

    The current Co-CEOs, Michael C. Riordan, former CEO of Greenville Health System and Charles D. Beaman Jr., former CEO of Palmetto Health, have been working together over the last two years to set a strong foundation of governance and leadership for Prisma Health. Six months ago, Beaman and Riordan began focusing on specific areas to ensure Prisma Health was operating efficiently. Riordan has been responsible for driving several strategic projects to position the organization for long-term success, including facilitating the CEO search. On Friday, May 31, he will conclude his final project and fulfill his commitment to the organization, at which time he will retire from Prisma Health. Beaman has been focused on Prisma Health operations and will fulfill his commitment to the organization and step down from Prisma Health upon O’Halla’s arrival.

     

    About Prisma Health

    Prisma Health is a not-for-profit health company and South Carolina’s largest private employer. We are committed to excellence in providing patient care, conducting clinical research and teaching the next generation of physicians, nurses, dentists and other medical professionals. Our organization was formed in late 2017 when Greenville Health System and Palmetto Health joined together, officially becoming Prisma Health in January 2019. With nearly 32,000 team members, 18 hospitals and more than 300 physician practice sites, Prisma Health serves more than 1.2 million patients annually – about one quarter of the state’s population. Our goal is to improve the health of all South Carolinians by improving clinical quality, the patient experience and access to affordable care. Our groundbreaking programs in cardiovascular, diabetes, neuroscience, oncology and orthopedics care – as well as our two renowned Children’s Hospitals – attract patients from throughout the Southeast. Ultimately, we are dedicated to transforming the health care experience for our patients and their families, our team members and our guests by bringing our purpose to life: Inspire health. Serve with compassion. Be the difference. For more information, visit PrismaHealth.org.

  • Sam Patrick posted an article
    South Carolina's Zylo Therapeutics partners with Hoth on lupus treatment see more

    NEW YORK, May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE).  CLE is a chronic autoimmune disease that affects the skin.

    Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; http://www.zylotherapeutics.com/

    Scientists at Einstein College of Medicine recently demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. This work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases.

    The work at Einstein supports the thesis that AEA loaded into Z-pods™ improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation.

    According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.

    "Management is extremely pleased to partner with Zylö Therapeutics, enhancing our portfolio of unique treatments for patients suffering from various dermatological related ailments," stated, Mr. Robb Knie, CEO of Hoth Therapeutics.  "Zylö's initial work shows significant promise in combating Cutaneous Lupus Erythematosus, and we look forward to working with them in order to bring this treatment to market."

    "We are thrilled to partner with Hoth, a company that is committed to innovative solutions and partnerships to develop treatments for diseases with a high unmet clinical need, such as lupus," said Scott Pancoast, CEO of Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods through the next stages of development, we expect to further demonstrate the important role that our patented Z-pod delivery system plays in improving treatment outcomes."

    The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

  • Sam Patrick posted an article
    KIYATEC closes on new round of financing see more

    GREENVILLE, SC. – May 1, 2019 – KIYATEC, Inc. today announced the initial $3 million closing of the company’s series B2 financing round. The round was led by VentureSouth and included LabCorp® (NYSE: LH).

    “This validation and confidence by our investors, coupled with the exciting progress of our clinical trials, puts us on the path toward the next phase of growth and development,” said Matthew Gevaert, CEO of KIYATEC. “We are particularly excited to welcome LabCorp as a new investor because of the depth and breadth of their expertise in oncology.  With the preclinical and clinical development strengths of LabCorp’s Covance Drug Development business, and their corporate position as a world leader in clinical testing, there is great potential synergy across the many ways KIYATEC’s technology can be used to improve cancer care.”

    Proceeds from the financing will go toward KIYATEC’s ongoing clinical study, 3D-PREDICT, to validate KIYATEC’s proprietary assay as a patient-specific predictor of response to cancer therapies for solid tumors. The test analyzes a patient’s live cancer cells, grown in KIYATEC’s laboratory within a biologically relevant 3D microenvironment, to determine whether those cells respond to guideline-recommended cancer drugs. The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors.

    The company has gained significant momentum in 2019.  Recently, at the 110th Annual Meeting of the American Association for Cancer Research (AACR), KIYATEC demonstrated leading capabilities in modeling and predicting response to immuno-oncology therapies including checkpoint inhibitors. On April 10, KIYATEC was one of 20 companies recognized nationally on Capitol Hill as part of the 2019 University Innovation & Entrepreneurship Showcase.  In the first quarter of 2019, KIYATEC added three clinical sites to its 3D-PREDICT study and expects to continue its momentum by adding additional sites in the second and third quarters.

     

    About KIYATEC, Inc.

    KIYATEC is dedicated to accurately modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision making and drive drug development. Our predictive clinical tests provide oncologists with patient-specific response profiles to current standard of care drugs prior to treatment selection. Our predictive 3D models are being used by leading biopharmaceutical companies to increase the success of their preclinical and clinical drug development programs as they develop the cancer therapies of the future. www.kiyatec.com.

  • Sam Patrick posted an article
    Prisma Health Center aims to identify, prevent cancer... see more

    As someone familiar with the devastation of a loved one’s cancer diagnosis, Steve Johnson has long been an advocate for knowing his own risks for developing the disease. So when a genetic test revealed he carried a BRCA1 gene mutation, a high indicator for breast cancer, he suggested his three daughters get tested as well. But when two of the three tested positive for the gene, and subsequent tests revealed one had developed breast cancer at a barely detectable point, knowledge of the family’s risk factors became truly life-saving.

    An innovative new initiative at the Prisma Health Cancer Institute aims to help people like the Johnsons identify and manage their risk factors for cancer, examining links between lifestyle, genetics and cancer formation, with the goal of eventually preventing cancer at its earliest molecular development.

     

    Read the complete story here...

  • Sam Patrick posted an article
    KIYATEC and OHSU initiate patient enrollment into key oncology clinical trial. see more

    GREENVILLE, S.C.-- KIYATEC, Inc., today announced that Oregon Health & Science University (OHSU) Knight Cancer Institute has initiated patient enrollment into KIYATEC’s clinical study, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies for solid tumors.

    In this clinical study, the test analyzes a patient’s live cancer cells, grown in KIYATEC’s laboratory within a biologically-relevant 3D microenvironment, to determine whether or not those cells respond to guideline-recommended cancer drugs. Evidence from the company’s earlier pilot study established a correlation between patient-specific predicted tumor response and actual patient clinical response to cancer therapy. The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors.

    At present, the OHSU Knight Cancer Institute is enrolling newly diagnosed and relapsed ovarian cancer patients into the 3D-PREDICT Study.

    “As a pioneer in personalized cancer care, the OHSU Knight Cancer Institute is deeply committed to optimizing appropriate therapy for our patients as early as possible following diagnosis, when the disease is most treatable,” said Dr. Koen De Geest, lead investigator of the clinical trial at OHSU. “Five-year survival among high-grade ovarian cancer patients is 30%, and we believe this test has the potential to help improve outcomes in the clinic.”

    “With cancer treatment, and especially ovarian cancer, time is of the essence and being able to measure patient-specific evidence of response and non-response before treatment begins can truly change the future of cancer care,” said Matthew Gevaert, CEO of KIYATEC. “We welcome OHSU to our clinical study and their participation will be integral as we work to deliver accurate predictions of patient response to cancer therapies, reducing the need for patients to undergo treatments that may not work.”

    The 3D-PREDICT study is anticipated to continue through 2022. Details on the trial can be found on https://clinicaltrials.gov/ct2/show/NCT03561207.

    About KIYATEC, Inc.
    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to therapies before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to 
    accurately predict treatment response prior to beginning treatment.

  • Sam Patrick posted an article
    Humimic is opening doors to a world of medical research from right here in South Carolina see more

    Accompanied by a contingent of life sciences leaders from SCBIO, the South Carolina Department of Commerce, Upstate Alliance, the Charleston Regional Development Alliance and others, South Carolina is making its presence felt at Arab Health 2019 -- the global medical and life sciences conference held annually in Dubai.  And Greenville's own Humimic Medical is making its own presence felt as well.

    Imagine a gelatin solution that mimics soft human tissue. One that doesn’t require refrigeration, and that opens doors to a world of medical industry research and training without the obstacles that come with cadavers.

    The product exists, developed eight years ago by Joel Edwards in his Arkansas basement. It was sparked by an idea, and initially sold to defense companies for testing under the name Clear Ballistics.

    In recent years, physicians and medical researchers took notice, prompting the spinoff of a company called Humimic Medical.

    Read on for the full story from Greenville Business Magazine.

     

  • Sam Patrick posted an article
    IVC, which produces dietary supplements, prescription and OTC products, is expanding. see more

    Company produces high quality dietary supplements, plus nutritional, prescription and OTC products, for leading U.S. and global retailers and contract customers

     

    GREENVILLE, S.C. June 18, 2018 – International Vitamin Corporation (IVC), which produces high quality dietary supplements along with nutritional, prescription and OTC products, will invest several million dollars and add a significant number of positions to expand operations at its Greenville County, S.C. facilities over the next several years.

    Founded more than 55 years ago, IVC produces high quality dietary supplements for leading food, drug, mass and club retailers in the United States. The company also produces nutritional, prescription and OTC products for contract customers around the world. IVC’s recognized ability to deliver on innovation, quality and supply chain efficiency has enabled IVC to become one of the largest and fastest growing private label nutritional supplement companies in the nutritional marketplace.

    “This expansion of our Greenville County presence represents an important step in the growth of our business,” said Steven Dai, President and CEO for International Vitamin Corporation. 

    “We have found Greenville County and the Upstate a welcoming and pro-business location to expand our business, serve our customers and accelerate IVC’s success as we focus our efforts on meeting growing demand from our customers,” Dai added.  “We appreciate the support of the Greenville Area Development Corporation, the city of Greenville, the South Carolina Department of Commerce, and all who joined to make this announcement a reality.”

    IVC will expand its operations at 4615 Dairy Road and 4611 Dairy Road in Greenville County, already employing more than 380 associates.  IVC will create “a meaningful number of additional skilled and professional positions in Greenville County over the next several years,” said Jill Stambler, Vice President Human Resources.

    “Greenville County is pleased with International Vitamin Corporation's decision to expand its business operations in Greenville County by producing well known dietary supplements and pharmaceutical products to the US and international markets as it has for over 50 years,” said H.G. “Butch” Kirven, Chairman of Greenville County Council. “This expansion means significant additional capital investment by the company here, coupled with a commitment to increasing job opportunities for local citizens.  The company's decision reflects the high caliber of Greenville county's workforce, our low tax rates, and the unparalleled quality of life unique to our area.”

    “IVC’s focus on the vitamins, minerals and supplements market and innovations in both manufacturing and supply chain show that our community continues to be a profitable place to do business,” said City of Greenville Mayor Knox White. “The expansion of their manufacturing facility along the I-85 corridor is further affirmation that Greenville is open for business and we are thankful for the IVC family’s trust and continued investment.”

    Hiring details for the additional positions to be filled will be announced in the near future, according to Stambler.  She adds, “We are currently looking for a number of positions on different shifts.”  Some include: 

    • Set-up Mechanics
    • Material Handlers
    • Operators
    • Turret Drivers
    • Manufacturing Supervisors
    • Warehouse Clerk
    • Warehouse Order Pickers
    • Warehouse Shippers

    Interested candidates may apply directly at the IVC website by visiting http://ivccareers.com.

    For more information about International Vitamins Corporation, visit them at www.ivcinc.com.

     

  • Sam Patrick posted an article
    KIYATEC growth supports upcoming programs to better predict patient response to oncology drugs see more

    GREENVILLE, SC. – May 29, 2018 – KIYATEC, Inc., a privately held company changing the future of cancer care by predicting patient response to oncology drugs prior to treatment, today announced an expansion of its leadership team with the appointment of two industry veterans. Charlene Knape has joined the company as Vice President of Clinical Affairs, and Timothy Decker as Vice President Commercial Operations.

    Mr. Decker, a twenty year industry leader with a proven track record of developing and commercializing oncology diagnostic services and pharmaceuticals, has assumed responsibility for pre-launch commercial strategic development along with tactical planning and execution to drive clinical product launches. Mr. Decker held roles of increasing responsibility in strategic and tactical marketing for a decade at G.D. Searle and Abbott Laboratories before joining Genomic Health, Inc.  Over an eight year span, he played a lead role as Director and Senior Director in the global launch, marketing, reimbursement and sales of Oncotype DX molecular diagnostic tests in breast, colon and prostate cancers. Mr. Decker subsequently served as Vice President of Marketing at Castle Biosciences, Inc., where he drove corporate and pipeline strategy, as well as in-line product strategy and revenue growth for its molecular diagnostic tests in melanoma. He joins the company from Mexico City-based Grupo Fármacos Especializados, where he served as Division Head, Oncology Diagnostics, responsible for developing reimbursement pathways and securing positive coverage decisions among public and private sector payers.

    With more than 25 years of experience working with diagnostic companies, Ms. Knape is responsible for leading the clinical development programs and clinical operations for KIYATEC’s pipeline for ovarian cancer, glioblastoma, rare tumors and triple negative breast cancer. She most recently served as Senior Director, Clinical Development for Inivata, a clinical cancer genomics company utilizing liquid biopsies for comprehensive genomic profiling of tumors. Prior to this, Ms. Knape served in Becton Dickinson’s Corporate Clinical Development group, responsible for global clinical quality and contracts. Ms. Knape spent five years with Micell Technologies as Senior Director of Clinical Affairs where she managed all global clinical activities for first-in-human and CE Marking studies for an implantable cardiovascular device from initiation through successful regulatory submission. As the company’s lead in clinical operations, Ms. Knape also built the team and initiated a 1,400-patient study in Europe and a 400-patient study in China. Previously, Ms. Knape served as Vice President, Clinical Affairs at EndoTex Interventional Systems, led the clinical functions for Avocet Medical and Somnus Medical Technologies and held clinical affairs positions in the Companion Diagnostics and Biorepository at LabCorp.

    “At this pivotal time in the company’s growth, we are thrilled to welcome Charlene and Tim to KIYATEC. These two newly created positions are critical as we expand our clinical programs in key therapeutic areas and further strengthen our plan for the broad adoption of our patient-specific response prediction tests,” said Dr. Matthew Gevaert, CEO of KIYATEC. “Their expertise and industry knowledge is unparalleled and they will be instrumental as KIYATEC continues toward its path of changing the future of cancer care by predicting patient response to chemotherapy before treatment begins. I’m so glad to have Tim and Charlene on our team as we move toward our goal of commercialization and helping patients receive optimal treatment at the earliest possible time.”

    KIYATEC will be attending the American Society of Clinical Oncology (ASCO) meeting being held June 1-5 in Chicago.

    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.

  • Sam Patrick posted an article
    Greenville-based Zylö Therapeutics is utilizing regional chemical/mechanical engineering in new ways see more

    Once home to a thriving textile industry replete with chemical and mechanical engineers working to improve the soil and machinery converting raw cotton into commercial goods, upstate South Carolina may be on the precipice of its next industrial revolution: medtech.

     

    Born from technology developed at the Albert Einstein College of Medicine, Greenville-based Zylö Therapeutics is utilizing the regional chemical/mechanical engineering expertise and support network to improve drug and nitric oxide delivery through a proprietary sustained delivery system called Nanopods. 

    Read the entire story here, courtesy of Medical Design & Outsourcing...

  • Sam Patrick posted an article
    Leading-edge innovators, top presenters headed for SEMDA's Medtech 2018 in South Carolina see more

    Leading-edge innovators present for recognition, reward at annual gathering of Southeastern who’s who in medical technology, devices and diagnostics


    Greenville, SC – April 27, 2018 – At least 23 organizations ranging from start-ups to well-established companies have been accepted to present their latest, ground-breaking innovations to entrepreneurs, innovators, angel investors and business leaders from across the life sciences space as the Southeastern Medical Device Association (SEMDA) 2018 Medtech Conference convenes in Greenville, SC May 2-4, 2018.  

    SEMDA -- a non-profit trade association focused on making the Southeast a world-class region for medical technology, device, and diagnostic companies – has invited 23 finalist companies to present at PitchRounds 2018 – a highly targeted venue for both “Seed” companies as well as later-stage organizations to present innovative ideas to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others.

    Companies from seven Southeastern states will present ground-breaking ideas and technologies to hundreds of industry leaders.  Host state South Carolina leads the way with 10 companies invited to present, followed by Georgia and Florida with three companies each.  North Carolina, Alabama, Virginia and Tennessee are also represented.

    Among the South Carolina companies invited to present are Zylo Therapeutics, Accessible Diagnostics, KIYATEC and Moterum from host city Greenville, while Charleston’s Sanguine Technologies and Cryogenix, and Columbia’s Proof Biotechnologies are also invited.

    Invitees from Georgia include Intent Solutions and nfant, both of Atlanta, while North Carolina entries include Diamond Othopedic of CharlotteMemphis, Tennessee’s Sweetbio, Birmingham’s Circulogene and Nashville’s Raiven are also featured invitees.

    Twelve Early-stage companies from the Carolinas, Alabama and Florida have been invited to present at PitchRounds, with four finalists to be selected to compete for $10,000 in prize money, while getting to meet investors and partners at sessions and networking receptions.  SCBIO, SCRA and global law firm Eversheds Sutherland are co-sponsors of PitchRounds.

    Among the featured speakers committed to present at the conference are keynoter Joe Lee, Executive Director of Life Sciences for JP Morgan; Andy Fish, Chief Strategy Officer of AdvaMed; and Denise Hines, North American Chair of the Health Information & Management Systems Society and current CEO of eHealth Services Group.   

    Joe Lee is Executive Director of Life Sciences for JP Morgan and leads the Middle Market Banking coverage of life science companies across the Southeast. Widely respected in life science industry circles, Mr. Lee will discuss key opportunity areas for growth in the Southeast and provide rapid-growth companies with counsel on how to prepare their organizations for success in the competitive space.

    Andrew Fish is Chief Strategy Officer of AdvaMed, the leading trade association advancing medical technology in the U.S. and around the world. As chief strategy officer, Mr. Fish leads the association’s strategic planning, oversees AdvaMed's global, regulatory, and payment departments, and coordinates the development and operations of AdvaMed’s membership divisions and sectors.

    Dr. Denise Hines is current Chair of the North America Board of the Health Information & Management Systems Society (HIMSS), and is actively involved in HIMSS’ Women in Health IT initiatives that promote diversity and recognition.  She is CEO of eHealth Services Group and serves as Executive Director of Georgia’s statewide health information exchange (HIE).

    “The Southeastern medtech industry as a whole shows incredible growth and promise, and the diverse entries from across the region reflect that growth,” said Jason Rupp, Executive Director of SEMDA.  “PitchRounds gives us the chance to see the future come to life before our eyes with cutting-edge innovation and game-changing advancements in medical technology, devices and diagnostics from some of America’s brightest minds.”

    The SEMDA conference typically attracts more than 400 executives in medtech and life sciences from throughout the United States and has become a must-attend for the medtech community. Registration is strong but space is still available, noted Mr. Rupp.  Persons interested in attending can review the agenda, speakers and registration details online at http://www.semda.net.

    “These presenters and companies demonstrate that SEMDA has evolved into a truly regional organization that embraces and represents a diverse collective of medtech startups, universities, corporate organizations, investment resources, suppliers and capabilities from across the southeastern United States,” Mr. Rupp added.

    About SEMDA

    The Southeastern Medical Device Association (SEMDA) is a regional non-profit trade association that supports and promotes medical device and medical device data system (MDDS) companies in the Southeast. Created in 2004, the association provides unique educational resources to accelerate device development and achieve commercial success with access to funding, education, and networking opportunities for medical device companies, inventors, physicians, investors, tech transfer offices, universities, sponsors, and service providers interested in growing the medical device industry in the Southeast.

     

     

     

    Invited and scheduled to present at PitchRounds 2018

     

    LATER STAGE (RAISING SERIES A OR LATER)

    Company

    Name

    City/Town

    ST

    Kiyatec

    Matt Gevaert

    Greenville

    SC

    Intent Solutions

    Sam Zamarippa

    Atlanta

    GA

    Moterum

    David Huizenga

    Greenville

    SC

    Diamond Orthopedic

    JD Williams

    Charlotte

    NC

    Circulogene

    Mike Mullen

    Birmingham

    AL

    Sweetbio

    Kayla Rodriguez Graff

    Memphis

    TN

    Xhale, Inc.

    Douglas Crumb

    Gainesville

    FL

    Embody LLC

    Jeffrey Conroy

    Norfolk

    VA

    nfant

    Lou Malice

    Atlanta

    GA

    Kyndermed

    Melanie Simmons

    Tallahassee

    FL

    Raiven

    Jim Stefansic

    Nashville

    TN

    Fraudscope

    Musheer Ahmed

    Atlanta

    GA

     

     

     

     

     EARLY STAGE

    Company

    Name

    City/Town

    ST

    Zylö Therapeutics

    Scott Pancoast

    Greenville

    SC

    Sanguine Technologies Inc.

    John Forrest

    Charleston

    SC

    Accessible Diagnostics, LLC

    John Warner

    Greenville

    SC

    VitalFlo

    Luke Marshall, Ph.D.

    Raleigh

    NC

    Cryogenix, LLC

    John Baatz

    Charleston

    SC

    Aravis BioTech LLC

    Jeffrey Anker

    Greenville

    SC

    Purilogics, LLC

    Jinxiang Zhou

    Greenville

    SC

    OrthoScrews, LLC

    Zoe Guckien

    Tuscaloosa

    AL

    DiaTech Diabetes Technology

    John Gray

    Tallahassee

    FL

    Proof Biotechnologies, Inc

    Chang Kang

    Columbia

    SC

    PivotSC LLC/ XtremedX

    Frank Patterson

    Greenville

    SC

     

     

  • Sam Patrick posted an article
    SEMDA Medtech 2018 is coming to Greenville, SC May 2-4. see more

    Conference Registration Surging for Initial Appearance in Greenville, SC as Southeastern medtech industry continues rapid scale up


    Greenville, SC – April 17, 2018 -- The Southeastern Medical Device Association (SEMDA) -- a non-profit trade association focused on making the Southeast a world-class region for medical technology, device, and diagnostic companies – has announced an initial group of featured speakers for the 2018 SEMDA Medtech Conference May 2-4, 2018.

    For the first time ever, the annual Southeastern showcase of who’s who and what is happening in medtech will convene in South Carolina, with the Hyatt Regency Greenville serving as headquarters hotel.

    Among the featured speakers announced today that have committed to present at the conference are Joe Lee, Executive Director of Life Sciences for JP Morgan; Andy Fish, Chief Strategy Officer of AdvaMed; and Denise Hines, North American Chair of the Health Information & Management Systems Society and current CEO of eHealth Services Group.  Also speaking will be Lee Burnes, Vice President of Global Research & Development at Halyard Health; and Jim Stefansic, Chief Executive Officer of Raiven Healthcare

    Additional featured speakers are expected to be named shortly, and companies engaged in presenting to industry executives in the PitchRounds program, co-sponsored by SCRA, SCBIO and Eversheds Sutherland, will be announced within the week.  PitchRounds is a highly targeted event for both start-ups and “Seed” companies as well as later-stage (Series A or later) organizations to present ideas, innovations and products to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others in structured sessions.  Selected participants receive individual feedback on their presentations and compete for $10,000 in top prize money.

    “The South Carolina medtech industry has been a strong supporter of SEMDA for many years and is growing at one of the fastest rates in the country, so we are excited to tap into the growth and excitement in the industry by bringing this preeminent event to the Palmetto State for the first time,” said Jason Rupp, Executive Director of SEMDA.  “Most importantly, we are thrilled to unveil members of a stellar group of industry experts who will be presenting to members drawn from across the Southeastern United States and to industry attendees from across North America.”

    The SEMDA conference typically attracts more than 400 executives in medtech and life sciences from throughout the United States and has become a must-attend for the medtech community. Registration is currently surging, noted Mr. Rupp, and a full house of medtech industry leaders is again expected.  Persons interested in attending can review the agenda, speakers and registration details online at http://www.semda.net.

    Joe Lee, who will keynote Day 2 of the conference, is Executive Director of Life Sciences for JP Morgan and leads the Middle Market Banking coverage of life science companies across the Southeast. Well-known and respected in life science industry circles, Mr. Lee will discuss key opportunity areas for growth in the Southeast and provide rapid-growth companies with counsel on how to prepare their organizations for success in the competitive space.

    Andrew Fish is Chief Strategy Officer of AdvaMed, the leading trade association advancing medical technology in the U.S. and around the world. As chief strategy officer, Mr. Fish leads the association’s strategic planning, oversees AdvaMed's global, regulatory, and payment departments, and coordinates the development and operations of AdvaMed’s membership divisions and sectors.

    Dr. Denise Hines is current Chair of the North America Board of the Health Information & Management Systems Society (HIMSS), and is actively involved in HIMSS’ Women in Health IT initiatives that promote diversity and recognition.  She is CEO of eHealth Services Group and serves as Executive Director of Georgia’s statewide health information exchange (HIE).

    Lee Burnes is Vice President of Global R&D for Halyard Health where the organization is focused on development of products, technologies and solutions that prevent infection, eliminate pain and speed recovery.  Prior to joining Halyard, Lee successfully led numerous R&D organizations at Covidien.

    Jim Stefansic serves as President and CEO of Raiven Healthcare, a provider of healthcare artificial intelligence and data analytics solutions. An accomplished entrepreneur, Jim has years of experience launching and growing numerous healthcare technology businesses.  He previously was co-founder and COO of Pathfinder Therapeutics, Inc., where he helped bring industry-leading image-guided surgical products to market.

    “These presenters and others we will announce shortly demonstrates that SEMDA has evolved into a truly regional organization that embraces and represents the collective of medtech startups, universities, corporate organizations, investment resources and capabilities across the southeastern United States,” Mr. Rupp said.  “The conference provides a great opportunity to interact with other companies, investors, customers, partners, and specialized service providers.”

    # # #

     

    About SEMDA

    The Southeastern Medical Device Association (SEMDA) is a regional non-profit trade association that supports and promotes medical device and medical device data system (MDDS) companies in the Southeast. Created in 2004, the association provides unique educational resources to accelerate device development and achieve commercial success with access to funding, education, and networking opportunities for medical device companies, inventors, physicians, investors, tech transfer offices, universities, sponsors, and service providers interested in growing the medical device industry in the Southeast.

  • Sam Patrick posted an article
    South Carolina Innovators, Inventors convene at SEMDA conference to present to Venture Capitalists see more

    State’s Innovators, Inventors, convene at conference to present to Venture Capitalists

     

    GREENVILLE, SC – April 6, 2018 – The Southeastern Medical Device Association (SEMDA) -- a non-profit trade association driven to make the southeast a world-class region for medical technology, device, and diagnostic companies – brings its 2018 conference to South Carolina for the first time May 2-4, 2018, attracting hundreds of executives to Greenville to meet, negotiate, learn, network and grow the medical device industry in the Southeast.

    Focused on accelerating device development and helping organizations and individuals gain access to funding, education, and networking opportunities, the annual conference is a must-attend for medical device companies, inventors, physicians, investors, tech transfer offices, universities, and service providers interested in growing the medical device industry in North America, and even globally.

    As part of SEMDA 2018’s many activities, SCBIO and SCRA are collaborating to present PitchRounds 2018 – a highly targeted venue for both start-ups and “Seed” companies as well as later-stage (or Series A or later) organizations to present their ideas, innovations and products to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others in structured sessions. 

    Selected participants will receive individual feedback on their presentations and compete for $10,000 in top prize money for selected winners.  Participating presenters also receive two full conference registrations and access to meet with investors and partners at sessions and networking receptions.  Global law firm Eversheds Sutherland, one of the 50 largest law firms globally, is also a co-sponsor of PitchRounds.

    Applying to present is both free and simple, with full details available online at www.SEMDA.net/conference/pitchrounds or at www.SCBIO.org.  The deadline to complete the simple application to be considered is close of business April 13, 2018.

    SCBIO Vice President Erin Ford noted, “SCBIO and our co-sponsors are delighted to make PitchRounds a possibility for South Carolina’s emerging medtech companies to showcase their innovations and solutions, and to directly access investors and industry leaders to gain direct feedback on their innovations.”

    “While entries will be considered from across the entire Southeast and presentation spots are limited, we are confident that South Carolina will be well represented based on the robust pipeline of innovations the South Carolina life sciences community has been working on.  We encourage all early- and later-stage companies to enter the PitchRounds program and showcase the Palmetto State’s talents.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

  • Sam Patrick posted an article
    Zylö Therapeutics is locating new operations in Greenville County, SC. see more

    GREENVILLE, S.C. – Zylö Therapeutics, a developer of state-of-the-art technology for the pharmaceutical industry, is locating new operations in Greenville County. The company is expected to create 30 new jobs.

     

    Zylö Therapeutics has developed an innovative sustained-release drug-delivery system that delivers traditionally hard-to-deliver therapeutic agents through topical administration. With more than 10 years of research and development, the second generation of this technology continues to improve, providing 24-hour sustained release of a variety of agents, including nitric oxide, curcumin, lidocaine and more.

     

    Zylö Therapeutics is headquartered at the NEXT on Main facility at 101 North Main Street in Greenville, S.C. NEXT is a program of the Greenville Chamber of Commerce that currently supports more than 100 knowledge-based companies in Upstate South Carolina.

    Zylö Therapeutics’ operations will soon include a lab facility, where formulation and product development work will be performed. Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information.

     

    QUOTES

     

    “With the bulk of our scientists and advisors located in the Northeast corridor, we considered a variety of alternative locations, but Greenville represents a wonderful balance of small-town feel, sophistication, high growth and vibrancy. In addition, the city offers a wealth of start-up resources that will assuredly work to our advantage over time.” – Zylö Therapeutics CEO Scott Pancoast

     

    “To see a company like Zylö Therapeutics choose to invest in our state and our people is an important sign to the business community around the world that South Carolina is the place to be. We’ve worked hard to create a pro-business environment and cultivate a highly-trained workforce, and those efforts continue to pay off.” –Gov. Henry McMaster

     

    “The success of South Carolina’s booming life sciences industry continues to impress, and I congratulate Zylö Therapeutics on today’s tremendous announcement. Over the last two decades, we’ve seen a major transformation in South Carolina’s economy, and innovative companies like Zylö Therapeutics are responsible for it.” –Secretary of Commerce Bobby Hitt

     

    “Greenville County encourages growth in the bioscience sector of our economy. We are proud to welcome Zylö Therapeutics to Greenville as part of our vibrant bioscience community that is pioneering state-of-the-art technologies at the forefront of modern medicine. We wish great success for Zylö Therapeutics.” –Greenville County Council Chairman H.G. “Butch” Kirven Jr.

     

    “Greenville has become increasingly attractive to industry leaders in next-generation medical care, as innovative companies like Zylö Therapeutics seek environments that can help connect resources, support emerging technologies and supply a dedicated workforce. The City of Greenville is thrilled to welcome Zylö to our vibrant downtown and we look forward to being a part of their company’s growth.” –City of Greenville Mayor Knox White

     

    “We are excited to welcome Zylö Therapeutics as the newest member of NEXT and the Greenville startup community. This high-impact, knowledge-based company further strengthens the more-than-150 companies within this vibrant, entrepreneurial ecosystem.” –NEXT CEO John Moore


    FIVE FAST FACTS

     

    • Zylö Therapeutics is locating new operations in Greenville County.
    • The start-up is projected to create 30 new jobs.
    • Zylö Therapeutics is a developer of patented, state-of-the-art technology for the pharmaceutical industry.
    • Headquartered in Suite 315 at 101 North Main Street in Greenville, S.C., the company’s operations will include a laboratory facility focused on formulation and product development.
    • Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information.